ReferenceRRK6629
ENHANCE
A 52-week placebo-controlled randomized Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)
Research Summary
| Research Overview | |
|---|---|
| Project Status | Open |
| Proposed End Date | 21/11/2020 |
| Study Run through CRF? | No |
| Target number of patients agreed to recruit | 2 |
| Recruitment so far | 0 |